TBI impairs growth hormone production, disrupting cognition, memory and sleep
In healthy individuals, the model was able to identify sleep stages with an 83.7% accuracy when using a single frontal electroencephalography channel (EEG), and with an 83.9% accuracy when supplemented with electrooculogram (EOG). In patients with suspected OSA, the model achieved accuracies of 82.9% (single EEG channel) and 83.8% (EEG and EOG channels). The single-channel accuracies ranged from 84.5% for individuals without OSA to 76.5% for severe OSA patients. The accuracies achieved by the model are equivalent to the correspondence between experienced physicians performing manual sleep scoring. However, the model has the benefit of being systematic and always following the same protocol, and conducting the scoring in a matter of seconds.
According to the researchers, deep learning enables automatic sleep staging for suspected OSA patients with a high accuracy. The study was published in IEEE Journal of Biomedical and Health Informatics.
The Sleep Technology and Analytics Group, STAG, at the University of Eastern Finland solves sleep diagnostics challenges by using a variety of different approaches. The methods developed by the group are based on wearable, non-intrusive sensors, better diagnostic parameters and modern computational solutions that are based on artificial intelligence. The new methods developed by the group are expected to significantly improve OSA severity assessment, promote individualized treatment planning and more reliable prediction of OSA-related daytime symptoms and comorbidities Source:
University of Eastern Finland Journal reference:
Korkalainen, H., et al . (2019) Accurate Deep Learning-Based Sleep Staging in a Clinical Population with Suspected Obstructive Sleep Apnea. IEEE J Biomed Health Inform . doi.org/10.1109/JBHI.2019.2951346 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology